links for 2010-03-30

"The patents gave Myriad Genetics a virtual monopoly on such predictive testing for breast and ovarian cancer. Women who fear they may be at an increased risk are barred from having anyone look at their BRCA1 and BRCA2 genes or interpret them except for the patent holder, which charges about $3,000 for a test." This is good news, especially since the patent system is so thoroughly broken.

Holy crap, what a story. Good use of 15 minutes of your time.